We are pleased that Novartis has advanced BW-20829 into Phase 2b clinical development” said Dr. Dongxu Shu, Co-Founder, Chairman of the Board, and Chief Executive Officer of Argo Biopharma. “This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results